Therapeutic efficacy of erlotinib on human AML xenografts in SCID mice. (A,B) Cytologic and histopathologic features of KG-1 cells injected into SCID mice. Forty days after intraperitoneal inoculation of 106 KG-1 cells, ascites was subjected to Wright-Giemsa staining (A) and abdominal tumors were analyzed by HE staining (B) to demonstrate the presence of AML cells in the tissues. (C) Representative mice that were vehicle-only or erlotinib-treated with the presence or absence of abdominal tumor masses are shown. (D) Kaplan-Meier plot showing tumor-free survival. Mice were inoculated with KG-1 cells on day 0, and oral erlotinib administration was started on day 7 (5 days per week, 100 mg/kg per day). This experiment has been repeated once, yielding similar results.
